IMMP - Immutep: Realizing The Expected Catalysts With More To Come
2024-05-01 12:39:01 ET
Summary
- Immutep Limited is focused on developing novel treatments targeting LAG3, an immune checkpoint, for various tumor types.
- The company's pipeline includes eftilagimod, which has shown promising response rates in thoracic malignancies.
- Immutep should have sufficient funding for 9–10 quarters of research and has demonstrated promising early signals of efficacy and safety.
Topline Summary and Update
Immutep Limited ( IMMP ) is a company I've covered for a few quarters now, with my most recent outing providing a highlight for what I expected would be an exciting 2024. They are focused mainly on developing novel treatments targeting LAG3, an immune checkpoint with a now-established role in the management of melanoma. IMMP is one of the companies trying to push this strategy into other tumor types....
Immutep: Realizing The Expected Catalysts, With More To Come